Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

C & O Pharmaceutical Technology ( Holdings) Company Profile - Aug 14, 2011

VIEWS: 65 PAGES: 10

C & O Pharmaceutical Technology (Holdings) Limited (C&O) is an integrated pharmaceutical company in the People's Republic of China. C&O is engaged in the research and development, manufacturing, as well as marketing and distribution of C&O branded and third party pharmaceutical products through a distribution network covering over 2,000 distributors and 300,000 clinics, pharmacies and hospitals across China. Its product portfolio comprises products focusing primarily on anti-infection and gastrointestinal drugs, drugs for ageing adults, as well as other specialized drugs. It offers one-stop solutions to other pharmaceutical companies both in China and outside of China with its contract research organization (CRO) and contract manufacturing organization (CMO) services, as well as product registration and distribution services. It has three segments: Development, manufacture and sales of pharmaceutical products; Distribution of pharmaceutical products, and Sales of technical know-how.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   C & O Pharmaceutical Technology
   ( Holdings) Ltd                                                                       440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.



  COMPANY PROFILE
  Figures in Chinese Renmimbi

                                 Wright Quality Rating:DANN                                Key Data

   C & O Pharmaceutical Technology (Holdings) Limited (C&O) is an integrated               Ticker:
   pharmaceutical company in the People's Republic of China. C&O is engaged in the         E92
   research and development, manufacturing, as well as marketing and distribution of
   C&O branded and third party pharmaceutical products through a distribution network      2010 Sales:
   covering over 2,000 distributors and 300,000 clinics, pharmacies and hospitals across
                                                                                           572,307,158
   China. Its product portfolio comprises products focusing primarily on anti-infection
   and gastrointestinal drugs, drugs for ageing adults, as well as other specialized
   drugs. It offers one-stop solutions to other pharmaceutical companies both in China     Major Industry:
   and outside of China with its contract research organization (CRO) and contract         Retailers
   manufacturing organization (CMO) services, as well as product registration and
   distribution services. It has three segments: Development, manufacture and sales of     Sub Industry:
   pharmaceutical products; Distribution of pharmaceutical products, and Sales of          Drug Store Chains
   technical know-how.
                        Stock Chart                                  Officers              Country:
                                                              Non Executive Chairman       China
                                                                   Tatsuya Suto
                                                                                           Currency:
                                                               Chief Financial Officer
                                                                                           Chinese Renmimbi
                                                                   Kwok Fung Choi

                                                                                           Fiscal Year Ends:
                                                                     Secretary
                                                                    Lan Sim Lim            June

                                                                                           Employees
                                                                                           222

                                                                                           Exchanges:
                                                                                           SIN

                                                                                           Share Type:
                                                                                           Ordinary


              Stock Price (8/12/2011): 2.50                                                Market Capitalization:
                Recent stock performance                                                   1,659,905,827
                    1 Week       0.6%
                    4
								
To top